Jaguar Health Secures Exclusive License for FDA-Approved Oral Mucositis Gel, Targets Q3 2024 Commercial Launch

Jaguar Health, Inc. has entered an exclusive five-year in-license agreement with Venture Life Group PLC for the U.S. distribution of Gelclair®, a FDA-approved treatment for oral mucositis. The licensing deal aligns with Jaguar's strategic focus on cancer supportive care, marking its third prescription product. Oral mucositis, often caused by cancer treatments, affects up to 40% of chemotherapy patients and up to 90% of patients with head and neck cancers.

Gelclair differentiates itself by managing pain without numbing, offering a protective gel that adheres to the mouth's mucosal surface, providing relief for various conditions, including lesions from cancer treatment. It stands out in the market by not causing stinging sensations, common in similar products. The product is part of Jaguar's broader strategy to expand its portfolio into cancer-related care, building on its existing work in HIV-related support.

Lisa Conte, CEO of Jaguar, highlighted the benefits of Gelclair in managing oral mucositis in cancer patients, enhancing their quality of life and treatment sustainability. The product's introduction is poised to meet a critical need within oncological care by preventing severe complications and supporting sustained nutritional intake without invasive interventions.